cardial oxygen consumption. It has also been suggested (Fam & McGregor 1964 ) that they divert blood from the ischemic myocardium through competitive vasodilatation in adjacent muscle, a theory with which we disagree. The failure of these drugs in angina has discouraged their trial in other aspects of ischmmic heart disease and I wish to discuss two other possibilities.
Following acute myocardial infarction survival and recovery are determined to a large extent by the development of a collateral circulation. Little is known about the rate at which this develops in man but Fulton (1965) has shown that collateral vessels may eventually enlarge greatly in patients with chronic ischvmic heart disease, and may carry the bulk of the myocardial blood supply.
In dogs we have studied the development of this collateral supply by measuring collateral flow each day after acute myocardial infarction. Serial measurements are usually unchanged for three days, but after this a progressive rise in collateral flow commences, continuing into the normal range by about the tenth day. This increase has been found to coincide with enlargement of the interarteriolar anastomoses (Rees & Redding 1 967a).
These changes, and the effects of dipyridamole on successive days, are shown in Fig 7. In the early stages the effect of the vasodilator is slight, but after twenty-four hours a progressive rise in collateral flow results from its administration which precedes the natural increase in collateral flow (Rees & Redding 1967b) . It is not yet known what effects powerful coronary vasodilators may have in patients with acute myocardial infarction, but if the same time relationships apply some benefit might be expected in the later days of recovery.
Ischxmia is the stimulus for this collateral vessel growth, but it is of interest that it can also develop in hearts without coronary disease under the stimulus of anamia (Zoll & Norman 1952 , Eckstein 1955 . Recently it has been suggested that powerful coronary vasodilator drugs may also stimulate collateral vessel growth in normal hearts (Blachrnan et al. 1964 , Schaper et al. 1965 and thus protect the animals from the effects of subsequent coronary obstruction.
These various stimuli, ischamia, anamia and drugs, promote collateral vessel growth by causing prolonged vasodilatation. Schaper (1967) has shown that the resistant increase in tangential wall stress leads to cell division in the vessel wall, thus permitting enlargement. The interesting problem is whether such collateral vessel development can be promoted in man by vasodilator drugs and, if so, whether it will offer any practical benefit. Drugs commonly used in the treatment of hypertension achieve their effect by inhibiting cardiovascular responses that maintain blood pressure. The physiological effects of ganglion-blocking drugs, sympathetic neurone blocking drugs and methyldopa, have many features in common that are characteristic of inhibition of the sympathetic vasoconstrictor supply to blood vessels. However, the modification of cardiovascular responses in patients where blood pressure is lowered by the P adrenergic receptor blocking drug propranolol shows important differences. These differences have important clinical significance. Sectio)n of Medicine with Sectioni of Experimezttal Medicin1e and Therapeutics Ganglionic Blockade The vasomotor centre, in the midbrain, regulates the diameter of blood vessels by means of variation of sympathetic vasoconstrictor tone. The methonium compounds (Paton & Zaimis 1949) , the most potent being penta-and hexamethonium, were the first drugs used clinically to interfere with this pathway, blocking transmission through the ganglia by competitively inhibiting the action of acetylcholine (Paton & Zaimis 1951) . The erect position results in an increase in sympathetic tone to counteract the effect of gravity, so it is not surprising that inhibition of transmission through ganglia results in a postural drop of blood pressure (Arnold & Rosenheim 1949) . Besides interference with the innervation of the arteries, an inhibition of sympathetic venous tone, particularly in the erect position, is important in the hypotension produced by hexamethonium. A fall in venous pressure may precede the fall in arterial pressure (Restall & Smirk 1952 , Smith & Hoobler 1956 ); this results from peripheral pooling of the blood and the reduced venous return leads to a fall in cardiac output (Hoobler et al. 1955 ).
Ganglion-blocking drugs, therefore, easily produce large postural falls of blood pressure, leading to symptoms of postural hypotension. Other physiological events (vide infra) that are normally associated with increased sympathetic activity to blood vessels also enhance the physiological consequences of sympathetic inhibition. As these drugs also block parasympathetic ganglia they produce other side-effects, principally difficulty in visual accommodation, dry mouth, constipation, difficulty wvith micturition, and impotence.
Blockade of the Sympathetic Neurone
(a) Guanethidiine: The disadvantages of parasympathetic blockade were overcome by the introduction of guanethidine (Maxwell et al. 1959 , Page & Dustan 1959 and bretylium (Boura et al. 1959) , although the latter is now obsolete because tolerance frequently develops.
The site of action of guanethidine is the sympathetic nerve endings, to inhibit the release of noradrenaline. Action potentials in the nerve trunk are not inhibited, and the receptor is not blocked. The effect of injected noradrenaline is actually potentiated (Maxwell et al. 1960 , Green & Robson 1965 , possibly due to some direct sensitizing effect of guanethidine on smooth muscle (Krayer et al. 1962 reserpine (Bein 1960) and the a receptor antagonist phentolamine. Guanethidine depletes tissue amines but, in contrast to reserpine, not those of the adrenal medulla (see Bein 1960) . ). After a period of adjustment, the patients were given each drug for three months in random order; the aim of the trial was to control the standing diastolic pressures to a similar level. The postural and exercise hypotension from guanethidine is apparent. After guanethidine, standing results in a fall of cardiac output similar to that seen with ganglionic blockade (Dollery et al. 1961 ). Guanethidine inhibits venoconstriction in normals (Mason & Braunwald 1964) and the attendant increase in venous capacity reduces venous return, and so this may be at least partly responsible for the reduced cardiac output. Guanethidine interferes with the sympathetic to the heart and this also tends to reduce cardiac output.
(b) Bethanidine: Bethanidine prevents the release of noradrenaline at sympathetic nerve endings and enhances the effect of injected noradrenaline, but unlike guanethidine it does not deplete tissue amines (Boura & Green 1963 ).
The need for increased sympathetic activity enhances physiological consequences of sympathetic inhibition from bethanidine, the hypotensive action is increased in the erect posture (Montuschi & Pickens 1962 , Johnston et al. 1964 ) and there is a further drop of blood pressure on exercise ).
From Fig 1 it can be seen that the falls in blood pressure in the erect position and on exercise are slightly greater on bethanidine than on guanethidine. This was confirmed in 17 patients who each had similar standing diastolic blood pressures on both guanethidine and bethanidine. The average standing diastolic blood pressures were in the range 80-100 mmHg with no greater difference than 10 mmHg between the averages on either drug in an individual patient. These patients hence each received equivalent doses of both drugs. Analysis showed a small but statistically significant increase in postural and exercise hypotension on bethanidine compared to guanethidine ).
This slightly greater fall of blood pressure on standing and on exercise after bethanidine compared to guanethidine could be predicted from the animal experiments of Boura & Green. Using the electrically stimulated cat nictitating membrane preparation, which is innervated by the sympathetic, it was found that guanethidine abolished the response to low frequency stimulation but above the threshold of response did not affect the slope relating frequency of sympathetic nerve stimulation to the resultant contraction of the cat nictitating membrane (Boura & Green 1962) . Bethanidine, however, depressed the slope; thus at higher rates of stimulation there was relatively greater blockade than seen with guanethidine, but at a low rate of stimulation the response was relatively less inhibited (Boura & Green 1963) . Increased sympathetic activity (i.e. equivalent to high rates of stimulation) is required to maintain the blood pressure in the standing position. When guanethidine and bethanidine are given as outlined above in a dosage to produce equivalent effect in the standing position, guanethidine with its relatively greater effect at low frequency of sympathetic activity, i.e. the supine position, would therefore be expected to produce a lower supine blood pressure than bethanidine with its relatively smaller effect at low rates of sympathetic activity.
Although guanethidine produces a statistically significant lower supine blood pressure for a given standing pressure than bethanidine, the difference is small; whether it is of clinical significance is another matter. In addition bethanidine appeared overall to produce fewer side-effects ).
(c) Methyldopa: Methyldopa also interferes with the function of the sympathetic neurone, although the precise mechanism is not clear (Prescott et al. 1966 ). It has been postulated that a-methyldopa is metabolized to a-methylnoradrenaline. This displaces the more powerful noradrenaline from its usual storage sites and acts as a much less potent transmitter (Day & Rand 1963) .
In common with the drugs blocking the sympathetic neurone, it produces a postural fall of blood pressure and blocks the overshoot of Valsalva's manceuvre (Dollery et al. 1963) . It lowers peripheral resistance and reduces cardiac output supine and standing (Dollery et al. 1963 ).
Fig 1 shows that the postural fall of blood pressure and exercise hypotension from methyldopa is less than is seen with guanethidine and bethanidine. Patients achieving closely similar average standing diastolic pressures on each drug over the three-month period of assessment (i.e. within the range 80-100 mmHg and within 10 mmHg) were compared on methyldopa against bethanidine, and against guanethidine. Methyldopa was found to produce less postural and exercise hypotension thaneither bethanidine or guanethidine ). Day & Rand (1963) found that the blocking effect of methyldopa on sympathetic activity was relatively greater at low rates of stimulation. This observation is in accord with the observations in man that methyldopa for an equivalent blockade at high rates of stimulation, i.e. standing position, produces a lower supine blood pressure, i.e. low sympathetic activity, than guanethidine or bethanidine.
(d) Other sympathetic blocking drugs: More recently introduced sympathetic blocking drugs, debrisoquine (Pocelinko & Abrams 1964 , Kitchin & Turner 1966 ) and guanoclor (Sinniah & Gatenby 1965) , also have the disadvantages inherent in this mode of action. Cardiovascular effects of sympathetic nieurone blockade: The various physiological events that stress the sympathetic and therefore potentiate the hypotensive effect of sympathetic blocking drugs, whether acting at ganglia or sympathetic nerve endings, are included in Table 1 .
There are variations in the effect of sympathetic blocking drugs on the cardiovascular reflexes, to the increased hypotension in the erect posture and Section of Medicine with Section ofExperimental Medicine and Therapeutics 87 Hypertensive patients and to a lesser extent normotensives exhibit a diurnal variation in blood volume, volume in the morning being lower than in the afternoon (Cranston & Brown 1963) . This is probably the reason for the diurnal variation in blood pressure frequently seen in patients on treatment with sympathetic blocking drugs, e.g. guanethidine (Dollery et al. 1960) . The blood pressure is less and hence postural symptoms are more likely in the morning than later in the day.
Blockade of the Beta Adrenergic Receptor
Pronethalol was the first clinically useful drug to block the ,3 receptor (e.g. vasodilator and cardiac stimulator) and so prevent certain actions of adrenaline (Black & Stephenson 1962) . It was found to have a hypotensive action (Prichard 1964) , and propranolol (Black et al. 1964 ) also lowers the blood pressure (Prichard & Gillam 1964 , Frohlich etal. 1968 ).
Beta adrenergic blockade on the response to posture and exercise: Examples of patients who previously required large doses of sympathetic blocking drugs including methyldopa to treat their hypertension and were subsequently treated with propranolol have been reported , Prichard & Gillam 1968 ). exercise, as discussed above, and it seems probable that similar differences will be observed when the modification of the response of blood pressure to the other physiological events is assessed. The effect of environmental temperature is discussed below.
-SUp/ ___EmECr Figs 2-5 illustrate the supine and standing blood pressure of patients from the series reported by Prichard & Gillam (1968) . In the case recorded in Fig 2, blood pressure was previously controlled with guanethidine and on standing there was a considerable postural fall of pressure. pressure is lower and there is no postural hypotension. A patient with exercise hypotension on bethanidine is shown in Fig 3; this is no longer present after control of his blood pressure with propranolol. A further patient, previously being treated with methyldopa that was associated with a large postural fall of blood pressure, is illus- ); one of these patients could not tolerate guanethidine, 2 methyldopa. Subsequently they have been treated with propranolol (Prichard & Gillam 1968 ). On each of the four drugs the average of seven readings at the outpatient clinic was taken. The average diastolic standing blood pressures for bethanidine, methyl-Fig 5 Supine and erect blood pressur es during treatment with mnethyldopa, debrisoquine, reserpine and cyclopenthiazide, and over period of change to propranolol in a patient with fiundi grade III, blood utrea 4 7 ,ng/ 100 tnt and ECG left ventr-iciular-hYpertrophY dopa and propranolol were the same, 94 mmHg, for guanethidine 92 mmHg. The ratio of mean standing to mean supine blood pressure in these patients was: for propranolol I :1, bethanidine 0-79: 1, guanethidine 0-83: 1, methyldopa 0-88 :1 (a ratio of less than I : I indicating a postural drop of blood pressure). The ratio of mean exercise to mean supine blood pressure for propranolol was 101 : 1, bethanidine 0-72: 1, guanethidine 0-75: 1, methyldopa 0-87 : 1 (a ratio of less than 1 : 1 indicating exercise hypotension). In all these cases the difference between the ratios on propranolol and each of the other drugs, bethanidine, guanethidine and methyldopa, was significant, P 0 001. There were 6 patients who received no diuretics on any of the four drugs; the closely similar differences were observed and again the difference between propranolol and each of the other drugs was significant (P 0 001). increases the postural drop of blood pressure and exercise hypotension in patients on bethanidine or guanethidine (Prichard & Gillam 1969) . The lower post-exercise blood pressure at a higher environmental temperature was due to the larger postural fall in blood pressure, not to an increased fall from exercise itself. When the same 6 patients were given propranolol to treat their hypertension no progressive change in standing or postexercise blood pressure was observed on raising environmental temperature.
In a group of 4 patients on methyldopa there was no increase in the postural drop of blood pressure as temperature was increased.
Valsalva's manwuvre: The response of blood pressure to Valsalva's manceuvre in patients on Fig 2. Upper trace while on oral bethanidine (75 mg divided daily), lower trace while on oral propranolol (60 mg divided daily), in both instances with chlorothiazide sympathetic neurone blocking drugs and on propranolol has been studied (Prichard & Gillam 1969) . Fig 7 shows the response to Valsalva's manceuvre in a patient on bethanidine and later after treatment with propranolol. In the presence of bethanidine there is an absence of the usual vasoconstriction during effort and a consequent loss of overshoot, typical of inhibition of the sympathetic supply to blood vessels. The second trace recorded subsequently shows that on propranolol there is a good constrictor response, there is a rise of blood pressure during effort and some overshoot of blood pressure after cessation of effort.
Intravenous propranolol reduces the tachycardia that occurs during effort but does not reduce the vasoconstriction that occurs in this phase. It does, however, reduce the overshoot by reducing the response of the heart pumping blood into a constricted arterial circulation (Prichard & Gillam 1966) . Oniset of actioti of hypotensive drugs: Early clinical experience suggested that although a constant daily dose of propranolol rapidly produced its full bradycardia, the full hypotensive effect was delayed over some weeks. Formal studies confirm this (Prichard & Gillam 1969) ; there is a gradual fall of pressure over about six weeks, most of the fall in blood pressure occurring in the first three weeks. Fig 8, which shows the supine blood pressure, is an example of a formal experiment to illustrate this point. The patient was previously on bethanidine. His sensitivity to propranolol was assessed and he was started on propranolol 100 mg q.d.s. The day after starting on propranolol his pulse rate was 64 per min, there being 90 Pr-oc. roy. Soc. Med. Voluime 62 Januaray 1969 no further fall. His blood pressure fell over a period of three weeks and there was some further fall over the next three weeks.
The blood pressures were analysed in patients who had been seen under standard conditions in the outpatient clinic, and who had been followed up for at least three months prior to change to the drug concerned. The mean blood pressure both supine and standing in 22 patients on bethanidine, 22 on guanethidine, and 20 on methyldopa showed no change between the visit after stabilization and one month later (figures analysed from the study of ). In 14 patients on propranolol the mean supine pressure at the visit to outpatients after the final stabilization of the dose (on average three weeks later) was 112 mmHg (147/95), and the reading one month later, 104 mmHg (139/87), 0-005 > P > 0-001. There was also a progressive fall in the mean standing blood pressure over this time, 114 to 106 mmHg (0-02 > P --000 ) (Prichard & Gillam 1968 ).
Other-beta receptor blocking drugs: Propranolol has a local anesthetic action besides its ,3 receptor blocking action. Another recently described ,B blocking drug, INPEA (N-isopropyl-p-nitrophenylethanolarmine) has no local anasthetic action (Teotino et at. 1963 , Somani & Lum 1965 . INPEA has been given to a few hypertensive patients, and although preliminary results suggest that it produces a hypotensive effect, it produces more side-effects, e.g. nausea, vomiting, paresthesiae, tiredness, frequently necessitating withdrawal of the drug. Fig 9 illustrates a patient who previously took part in our trial of bethanidine guanethidine and methyldopa. Subsequently she received propranolol, which made her rather constipated, and so she has now been treated with INPEA, with reasonable control of her blood pressure.
Eflect of synipathetic blockade on the heart: Using doses of drugs to produce similar standing diastolic blood pressures, Prichard et al. (1968) found that, in the same patients, the average supine pulse rate on guanethidine was significantly slower than on bethanidine or methyldopa in both the supine and standing position. The difference in pulse rate between bethanidine and methyldopa in the standing position was significant. In the patients summarized in Fig 6 the supine and standing pulse rates on propranolol were significantly slower than on methyldopa or bethanidine, or guanethidine in the standing position only.
Propranolol reduces the cardiac output at rest in the supine position after intravenous administration in hypertensive patients ( (Frohlich et al. 1968 , in the standing position and on exercise ). The effect on the cardiac output after prolonged oral administration appears similar to that after intravenous administration.
Bethanidine, guanethidine and methyldopa reduce cardiac output as discussed above.
There are no within-patient studies comparing the effect of these drugs and of propranolol on cardiac output, although one is in progress comparing bethanidine and propranolol . Cardiovascular effects of blockade of cardiac sympathetic: These are summarized in Table 1 . How propranolol lowers the blood pressure is not known. We have tentatively suggested that its hypotensive action is a result of block of the cardiac sympathetic (Prichard & Gillam 1964 , Prichard 1964 It is postulated that the baroceptors are conditioned by the reduction in the peak of pressor responses to produce vasomotor inhibitory im pulses at a lower mean level. It seems likely that a-parallel situation exists when a patient with mild or moderately severe hypertension is put to bed, although it is a reduction in sensory stimuli (rather than a modification of the cardiovascular response) which leads to a fall in blood pressure. When blood pressure has been lowered by propranolol, although the baroceptors regulate the blood pressure at a lower mean level, there is a normal response to cardiovascular reflexes requiring acute alterations in vascular tone.
Summary
Sympathetic neurone blocking drugs cause alterations in various cardiovascular responses that are largely dependent on vasomotor control of the blood vessels. From the evidence of the effect on the response to posture, exercise and changes in environmental temperature, it seems that methyldopa causes less interference with responses than guanethidine, which in turn produces slightly less effect than bethanidine. Propranolol does not interfere with vascular responses to these physiological events, neither does it inhibit vasoconstriction during Valsalva's manceuvre. Hence for a similar standing diastolic blood pressure the supine pressure is highest with bethanidine, slightly lower with guanethidine, and considerably lower with methyldopa. As there is no standing fall of blood pressure from propranolol the supine diastolic pressure is usually lower than the standing pressure.
Dr R B Hedworth-Whitty (Queen Elizabeth Hospital, Birmingham) congratulated Dr Rees on developing a difficult technique in order to study the effect which drugs had on varying the perfusion in the coronary vascular bed of experimental animals.
He said that the measurement of myocardial blood flow in man was at present restricted to 'indirect techniques' of which xenon 133 was an example. This technique was suitable for use only when myocardial volume flow was homogeneous. Few methods were capable of measuring accurately low tissue or blood concentrations of indicator substance which occurred at the end of the myocardial 'wash-out' curve, but where the flow was homogeneous the last part or 'tail' of the curve could be eliminated from the calculation.
When there was regional inhomogeneity of flow, as in ischxmic heart disease in man, however, the last part of the 'wash-out' curve, which represented the less perfused areas, became very important and could not be ignored. In addition, Greene et al. (1967) had shown that the physical properties of an indicator gas determined whether 'tailing' of the 'wash-out' curve was present at all; and Dr Hedworth-Whitty himself had found that when nitrous oxide was used as the indicator gas
